Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Carcinosarcoma, Ovarian”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00003939
What this trial is testing

Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma

Who this might be right for
Brain and Central Nervous System TumorsEndometrial CancerGastrointestinal Stromal Tumor+3 more
European Organisation for Research and Treatment of Cancer - EORTC 132
Testing effectiveness (Phase 2)WithdrawnNCT06393751
What this trial is testing

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Who this might be right for
Platinum-Refractory Fallopian Tube CarcinomaPlatinum-Refractory Ovarian CarcinomaPlatinum-Refractory Primary Peritoneal Carcinoma+20 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Looking for participantsNCT04919629
What this trial is testing

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Who this might be right for
Fallopian Tube CarcinosarcomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+12 more
Roswell Park Cancer Institute 60
Testing effectiveness (Phase 2)Study completedNCT01010126
What this trial is testing

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Who this might be right for
Adult Hepatocellular CarcinomaAdvanced Adult Hepatocellular CarcinomaEndometrial Serous Adenocarcinoma+42 more
National Cancer Institute (NCI) 252
Not applicableUnknownNCT05537844
What this trial is testing

Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma

Who this might be right for
Ovarian CancerHigh Grade Serous CarcinomaCarcinosarcoma, Ovarian+4 more
Liz-Anne Lewsley 250
Testing effectiveness (Phase 2)Study completedNCT00245102
What this trial is testing

Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma

Who this might be right for
Adult AngiosarcomaAdult Epithelioid SarcomaAdult Leiomyosarcoma+12 more
National Cancer Institute (NCI) 147
Testing effectiveness (Phase 2)Ended earlyNCT05001282
What this trial is testing

Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Who this might be right for
Ovarian CancerOvarian NeoplasmsOvarian Carcinoma+22 more
Elucida Oncology 79
Not applicableEnded earlyNCT00904514
What this trial is testing

Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 241
Early research (Phase 1)Looking for participantsNCT06483048
What this trial is testing

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+13 more
Mayo Clinic 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT05147558
What this trial is testing

Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma

Who this might be right for
Uterine CarcinosarcomaAdvanced Uterine Carcinosarcoma
Memorial Sloan Kettering Cancer Center 40
Early research (Phase 1)Study completedNCT03552471
What this trial is testing

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Who this might be right for
BRCA1 Gene MutationBRCA2 Gene MutationFolate Receptor Alpha Positive+7 more
Ohio State University Comprehensive Cancer Center 25
Testing effectiveness (Phase 2)Looking for participantsNCT06638931
What this trial is testing

Agnostic Therapy in Rare Solid Tumors

Who this might be right for
Urachal CancerParathyroid CarcinomaFibrolamellar Carcinoma+38 more
Instituto do Cancer do Estado de São Paulo 28
Testing effectiveness (Phase 2)Looking for participantsNCT03686124
What this trial is testing

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

Who this might be right for
Refractory CancerRecurrent CancerSolid Tumor, Adult+1 more
Immatics US, Inc. 375
Testing effectiveness (Phase 2)Active Not RecruitingNCT03660826
What this trial is testing

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Who this might be right for
Endometrial AdenocarcinomaEndometrial Mixed Cell AdenocarcinomaEndometrial Serous Adenocarcinoma+3 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)UnknownNCT00003718
What this trial is testing

Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma

Who this might be right for
Endometrial CancerOvarian CancerSarcoma
Herbert Irving Comprehensive Cancer Center 25
Testing effectiveness (Phase 2)Study completedNCT05494580
What this trial is testing

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Who this might be right for
Ovarian CancerOvarian CarcinomaPlatinum-resistant Ovarian Cancer+2 more
Sun Yat-sen University 29
Testing effectiveness (Phase 2)Study completedNCT05619913
What this trial is testing

EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma

Who this might be right for
Ovarian CarcinosarcomaUterine Carcinosarcoma
Australia New Zealand Gynaecological Oncology Group 13
Early research (Phase 1)Looking for participantsNCT07690189
What this trial is testing

Study of NTB-928 in R/R OC

Who this might be right for
Relapsed/Refractory Ovarian Carcinoma
TeneoSeven, Inc. 90
Testing effectiveness (Phase 2)Study completedNCT03648489
What this trial is testing

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

Who this might be right for
Ovarian CancerOvarian NeoplasmsOvarian Carcinosarcoma+7 more
Imperial College London 134
Large-scale testing (Phase 3)UnknownNCT00954174
What this trial is testing

Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer

Who this might be right for
Mixed Mesodermal (Mullerian) TumorOvarian CarcinosarcomaRecurrent Fallopian Tube Carcinoma+39 more
GOG Foundation 637
Next Page
288